Exelixis Inc EXEL:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 3:41 PM EDT
22.58quote price arrow down-0.29 (-1.27%)
Volume
1,705,641
52 week range
18.08 - 24.34
Loading...
  • Open23.00
  • Day High23.23
  • Day Low22.51
  • Prev Close22.87
  • 52 Week High24.34
  • 52 Week High Date01/02/24
  • 52 Week Low18.08
  • 52 Week Low Date04/28/23

Key Stats

  • Market Cap6.846B
  • Shares Out303.19M
  • 10 Day Average Volume1.93M
  • Dividend-
  • Dividend Yield-
  • Beta0.57
  • YTD % Change-5.86

KEY STATS

  • Open23.00
  • Day High23.23
  • Day Low22.51
  • Prev Close22.87
  • 52 Week High24.34
  • 52 Week High Date01/02/24
  • 52 Week Low18.08
  • 52 Week Low Date04/28/23
  • Market Cap6.846B
  • Shares Out303.19M
  • 10 Day Average Volume1.93M
  • Dividend-
  • Dividend Yield-
  • Beta0.57
  • YTD % Change-5.86

RATIOS/PROFITABILITY

  • EPS (TTM)0.65
  • P/E (TTM)34.89
  • Fwd P/E (NTM)18.24
  • EBITDA (TTM)196.602M
  • ROE (TTM)8.74%
  • Revenue (TTM)1.83B
  • Gross Margin (TTM)96.04%
  • Net Margin (TTM)11.35%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Exelixis Inc

 

Profile

MORE
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously...
Stelios Papadopoulos Ph.D.
Independent Chairman of the Board, Co-Founder
Michael Morrissey Ph.D.
President, Chief Executive Officer, Director
Christopher Senner
Chief Financial Officer, Executive Vice President
Patrick Haley
Executive Vice President - Commercial
Jeffrey Hessekiel J.D.
Executive Vice President, General Counsel, Secretary
Address
1851 Harbor Bay Parkway
Alameda, CA
94502
United States

Top Peers

SYMBOLLASTCHG%CHG
MEDP
Medpace Holdings Inc
375.59-6.85-1.79%
HALO
Halozyme Therapeutics Inc
38.00-0.02-0.05%
ITCI
Intra-Cellular Therapies Inc
72.39-4.30-5.61%
NBIX
Neurocrine Biosciences Inc
132.37-0.86-0.65%
APLS
Apellis Pharmaceuticals Inc
47.40-0.63-1.32%